Yes, plaque in arteries can be partially reversed. Clinical trials using ultrasound imaging inside coronary arteries have documented measurable shrinkage of plaque after 12 to 24 months of aggressive cholesterol lowering. The reversal is modest, not a complete clearing of arteries, but it’s real and it correlates with fewer heart attacks and strokes.
That said, not all plaque responds equally. How much reversal you can achieve depends on how low your LDL cholesterol drops, how long you maintain it there, and what the plaque is made of. Here’s what the science shows about what’s actually happening inside your arteries and what it takes to turn things around.
How Plaque Shrinks at the Cellular Level
Atherosclerosis builds up when LDL cholesterol particles burrow into artery walls and trigger inflammation. White blood cells called macrophages rush in to clean up the cholesterol but end up gorging on it, becoming bloated “foam cells” that accumulate into fatty deposits. Over years, these deposits harden with calcium and fibrous tissue, narrowing the artery.
Reversal works by flipping this process. When LDL levels drop sharply, the ratio of HDL to LDL improves. HDL particles pull cholesterol out of those foam cells through a process called cholesterol efflux, essentially vacuuming fat out of the artery wall. At the same time, the macrophages themselves shift from an inflammatory type (M1) to an anti-inflammatory type (M2) that helps resolve damage rather than perpetuate it. Research in vascular biology has confirmed that this macrophage reprogramming is reversible and plays a central role in plaque stabilization and shrinkage.
This is why simply stopping plaque growth isn’t the same as reversing it. Regression requires enough HDL activity and low enough LDL levels to tip the balance so cholesterol is leaving the plaque faster than it’s entering.
What the Clinical Trials Found
The strongest evidence for plaque reversal comes from trials that used intravascular ultrasound (IVUS), a tiny probe threaded into coronary arteries to directly measure plaque volume. The ASTEROID trial, published in 2006, showed a 6.1% reduction in total plaque volume after 24 months of intensive statin therapy. That was one of the first clear demonstrations that atherosclerosis could go in reverse, not just slow down.
A later trial called GLAGOV went further by adding a PCSK9 inhibitor on top of statin therapy. Over 78 weeks, participants receiving the combination saw their plaque volume shrink by 0.95%, while the statin-only group saw essentially no change (a 0.05% increase). The difference was striking: the combination group achieved an average LDL of 36.6 mg/dL, compared to 93.0 mg/dL in the placebo group. The lower the LDL went, the more plaque shrank.
These numbers might sound small, but even modest reductions in plaque volume translate to meaningful drops in heart attack risk. Plaque that’s actively shrinking is also becoming more stable, less likely to rupture and trigger a sudden clot.
How Low LDL Needs to Go
The pattern across multiple trials is consistent: plaque regression becomes reliably measurable when LDL cholesterol drops below roughly 70 mg/dL, and the most dramatic results appear below 55 mg/dL. The latest 2026 ACC/AHA guidelines recommend a target of LDL below 55 mg/dL for people at very high cardiovascular risk, defined as those with a history of multiple heart attacks, strokes, or symptomatic peripheral artery disease.
For context, the average American adult has an LDL around 110 to 120 mg/dL. Getting to 55 or below typically requires high-intensity statin therapy, often combined with additional medications. The key takeaway is that moderate cholesterol reduction slows progression, but aggressive reduction is what drives actual reversal.
How Long Reversal Takes
Plaque doesn’t shrink overnight. Most imaging studies that detect regression use a follow-up period of 12 to 24 months. The ASTEROID trial measured its results at 24 months. Several CT-based studies have detected changes in plaque composition, specifically reductions in the soft fatty core, after 12 months of therapy. You shouldn’t expect a repeat scan to show dramatic differences in under a year.
It’s also worth understanding that plaque changes in stages. Early on, the soft lipid-rich core shrinks and the plaque becomes denser and more fibrous. This stabilization may be even more important than raw size reduction because it’s the soft, inflamed plaques that are most prone to rupturing. A smaller, more calcified plaque is far less dangerous than a large, fatty one, even if the total volume hasn’t changed much on a scan.
Lifestyle Changes and Plaque Reversal
Medication isn’t the only path. The Ornish Lifestyle Heart Trial remains one of the most cited demonstrations that intensive lifestyle changes alone can reverse coronary artery disease. Participants followed a program of a very low-fat whole foods diet (10% of calories from fat), three hours per week of moderate aerobic exercise, and one hour per day of stress management techniques like meditation or yoga.
After five years, the lifestyle group saw their average artery narrowing improve by 3.1 percentage points, a 7.9% relative improvement. The control group, following conventional medical advice, worsened by 11.8 percentage points, a 27.7% relative decline. The gap between the two groups was enormous.
The Ornish protocol is demanding, and not everyone can sustain it. But less extreme dietary patterns also show benefit. The CORDIOPREV trial, which ran for seven years, found that a Mediterranean diet rich in extra virgin olive oil reduced carotid artery wall thickness by about 0.03 mm over five to seven years, while a standard low-fat diet produced no measurable change. The Mediterranean diet also reduced the height of existing carotid plaques compared to the low-fat approach. These are modest changes, but they represent real structural improvement in artery walls over time.
How Doctors Track Plaque Changes
If you’re wondering how any of this gets measured, there are two main approaches. Inside clinical trials, IVUS (the ultrasound probe inside the artery) is the gold standard for precision. It can measure plaque volume down to fractions of a percentage. But it’s invasive and not practical for routine monitoring.
For most people, noninvasive options include coronary artery calcium (CAC) scoring, which uses a simple CT scan to estimate total calcified plaque burden, and coronary CT angiography (CCTA), which provides more detailed images of both calcified and soft plaque. CCTA has become increasingly popular because it can show not just how much plaque is present but what kind it is. Multiple studies show strong correlation between CCTA measurements and what IVUS finds inside the artery.
A CAC score is often the first step. If your score is zero, your near-term risk of a heart event is very low. A rising CAC score over time doesn’t necessarily mean you’re getting worse; sometimes plaque that was soft and dangerous is calcifying into a more stable form. That’s actually a sign of healing, which is why interpreting these numbers requires context rather than just tracking a single number.
What Reversal Actually Looks Like
It’s important to set realistic expectations. Even in the best clinical trials, plaque reversal is partial. Arteries don’t return to the pristine state of a 20-year-old. What happens is more like remodeling: the fatty, inflamed core of a plaque shrinks, the fibrous cap thickens and stabilizes, and the overall volume decreases by a few percent. For someone with significant coronary artery disease, that modest regression can mean the difference between a plaque that sits quietly and one that ruptures into a heart attack.
The practical implication is that plaque reversal is a long game. It requires sustained, aggressive management of cholesterol (through medication, lifestyle changes, or both), along with control of blood pressure, blood sugar, and inflammation. The earlier you start, the more reversible the plaque tends to be, because younger plaques have more lipid content and less calcium. Heavily calcified plaques in someone who’s had atherosclerosis for decades are harder to shrink, though they can still be stabilized.